The use of metformin is associated with decreased lumbar radiculopathy pain

Amber Taylor, Anton H. Westveld, Magdalena Szkudlinska, Prathima Guruguri, Emil Annabi, Amol M Patwardhan, Theodore J. Price, Hussein N. Yassine

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Lumbar radiculopathy pain represents a major public health problem, with few effective long-term treatments. Preclinical neuropathic and postsurgical pain studies implicate the kinase adenosine monophosphate activated kinase (AMPK) as a potential pharmacological target for the treatment of chronic pain conditions. Metformin, which acts via AMPK, is a safe and clinically available drug used in the treatment of diabetes. Despite the strong preclinical rationale, the utility of metformin as a potential pain therapeutic has not yet been studied in humans. Our objective was to assess whether metformin is associated with decreased lumbar radiculopathy pain, in a retrospective chart review. We completed a retrospective chart review of patients who sought care from a university pain specialist for lumbar radiculopathy between 2008 and 2011. Patients on metformin at the time of visit to a university pain specialist were compared with patients who were not on metformin. We compared the pain outcomes in 46 patients on metformin and 94 patients not taking metformin therapy. The major finding was that metformin use was associated with a decrease in the mean of "pain now," by -1.85 (confidence interval: -3.6 to -0.08) on a 0-10 visual analog scale, using a matched propensity scoring analysis and confirmed using a Bayesian analysis, with a significant mean decrease of -1.36 (credible interval: -2.6 to -0.03). Additionally, patients on metformin showed a non-statistically significant trend toward decreased pain on a variety of other pain descriptors. Our proof-of-concept findings suggest that metformin use is associated with a decrease in lumbar radiculopathy pain, providing a rational for larger retrospective trials in different pain populations and for prospective trials, to test the effectiveness of metformin in reducing neuropathic pain.

Original languageEnglish (US)
Pages (from-to)755-763
Number of pages9
JournalJournal of Pain Research
Volume6
DOIs
StatePublished - 2013

Fingerprint

Radiculopathy
Metformin
Pain
Phosphotransferases
Neuralgia
Adenosine Monophosphate
Therapeutics
Bayes Theorem
Visual Analog Scale
Chronic Pain
Public Health
Pharmacology
Confidence Intervals

Keywords

  • Adenosine monophosphate activated kinase
  • Diabetes
  • mTOR
  • Neuropathy

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Taylor, A., Westveld, A. H., Szkudlinska, M., Guruguri, P., Annabi, E., Patwardhan, A. M., ... Yassine, H. N. (2013). The use of metformin is associated with decreased lumbar radiculopathy pain. Journal of Pain Research, 6, 755-763. https://doi.org/10.2147/JPR.S52205

The use of metformin is associated with decreased lumbar radiculopathy pain. / Taylor, Amber; Westveld, Anton H.; Szkudlinska, Magdalena; Guruguri, Prathima; Annabi, Emil; Patwardhan, Amol M; Price, Theodore J.; Yassine, Hussein N.

In: Journal of Pain Research, Vol. 6, 2013, p. 755-763.

Research output: Contribution to journalArticle

Taylor, A, Westveld, AH, Szkudlinska, M, Guruguri, P, Annabi, E, Patwardhan, AM, Price, TJ & Yassine, HN 2013, 'The use of metformin is associated with decreased lumbar radiculopathy pain', Journal of Pain Research, vol. 6, pp. 755-763. https://doi.org/10.2147/JPR.S52205
Taylor, Amber ; Westveld, Anton H. ; Szkudlinska, Magdalena ; Guruguri, Prathima ; Annabi, Emil ; Patwardhan, Amol M ; Price, Theodore J. ; Yassine, Hussein N. / The use of metformin is associated with decreased lumbar radiculopathy pain. In: Journal of Pain Research. 2013 ; Vol. 6. pp. 755-763.
@article{52e5003791bb4d5f9f02eea2c228f677,
title = "The use of metformin is associated with decreased lumbar radiculopathy pain",
abstract = "Lumbar radiculopathy pain represents a major public health problem, with few effective long-term treatments. Preclinical neuropathic and postsurgical pain studies implicate the kinase adenosine monophosphate activated kinase (AMPK) as a potential pharmacological target for the treatment of chronic pain conditions. Metformin, which acts via AMPK, is a safe and clinically available drug used in the treatment of diabetes. Despite the strong preclinical rationale, the utility of metformin as a potential pain therapeutic has not yet been studied in humans. Our objective was to assess whether metformin is associated with decreased lumbar radiculopathy pain, in a retrospective chart review. We completed a retrospective chart review of patients who sought care from a university pain specialist for lumbar radiculopathy between 2008 and 2011. Patients on metformin at the time of visit to a university pain specialist were compared with patients who were not on metformin. We compared the pain outcomes in 46 patients on metformin and 94 patients not taking metformin therapy. The major finding was that metformin use was associated with a decrease in the mean of {"}pain now,{"} by -1.85 (confidence interval: -3.6 to -0.08) on a 0-10 visual analog scale, using a matched propensity scoring analysis and confirmed using a Bayesian analysis, with a significant mean decrease of -1.36 (credible interval: -2.6 to -0.03). Additionally, patients on metformin showed a non-statistically significant trend toward decreased pain on a variety of other pain descriptors. Our proof-of-concept findings suggest that metformin use is associated with a decrease in lumbar radiculopathy pain, providing a rational for larger retrospective trials in different pain populations and for prospective trials, to test the effectiveness of metformin in reducing neuropathic pain.",
keywords = "Adenosine monophosphate activated kinase, Diabetes, mTOR, Neuropathy",
author = "Amber Taylor and Westveld, {Anton H.} and Magdalena Szkudlinska and Prathima Guruguri and Emil Annabi and Patwardhan, {Amol M} and Price, {Theodore J.} and Yassine, {Hussein N.}",
year = "2013",
doi = "10.2147/JPR.S52205",
language = "English (US)",
volume = "6",
pages = "755--763",
journal = "Journal of Pain Research",
issn = "1178-7090",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The use of metformin is associated with decreased lumbar radiculopathy pain

AU - Taylor, Amber

AU - Westveld, Anton H.

AU - Szkudlinska, Magdalena

AU - Guruguri, Prathima

AU - Annabi, Emil

AU - Patwardhan, Amol M

AU - Price, Theodore J.

AU - Yassine, Hussein N.

PY - 2013

Y1 - 2013

N2 - Lumbar radiculopathy pain represents a major public health problem, with few effective long-term treatments. Preclinical neuropathic and postsurgical pain studies implicate the kinase adenosine monophosphate activated kinase (AMPK) as a potential pharmacological target for the treatment of chronic pain conditions. Metformin, which acts via AMPK, is a safe and clinically available drug used in the treatment of diabetes. Despite the strong preclinical rationale, the utility of metformin as a potential pain therapeutic has not yet been studied in humans. Our objective was to assess whether metformin is associated with decreased lumbar radiculopathy pain, in a retrospective chart review. We completed a retrospective chart review of patients who sought care from a university pain specialist for lumbar radiculopathy between 2008 and 2011. Patients on metformin at the time of visit to a university pain specialist were compared with patients who were not on metformin. We compared the pain outcomes in 46 patients on metformin and 94 patients not taking metformin therapy. The major finding was that metformin use was associated with a decrease in the mean of "pain now," by -1.85 (confidence interval: -3.6 to -0.08) on a 0-10 visual analog scale, using a matched propensity scoring analysis and confirmed using a Bayesian analysis, with a significant mean decrease of -1.36 (credible interval: -2.6 to -0.03). Additionally, patients on metformin showed a non-statistically significant trend toward decreased pain on a variety of other pain descriptors. Our proof-of-concept findings suggest that metformin use is associated with a decrease in lumbar radiculopathy pain, providing a rational for larger retrospective trials in different pain populations and for prospective trials, to test the effectiveness of metformin in reducing neuropathic pain.

AB - Lumbar radiculopathy pain represents a major public health problem, with few effective long-term treatments. Preclinical neuropathic and postsurgical pain studies implicate the kinase adenosine monophosphate activated kinase (AMPK) as a potential pharmacological target for the treatment of chronic pain conditions. Metformin, which acts via AMPK, is a safe and clinically available drug used in the treatment of diabetes. Despite the strong preclinical rationale, the utility of metformin as a potential pain therapeutic has not yet been studied in humans. Our objective was to assess whether metformin is associated with decreased lumbar radiculopathy pain, in a retrospective chart review. We completed a retrospective chart review of patients who sought care from a university pain specialist for lumbar radiculopathy between 2008 and 2011. Patients on metformin at the time of visit to a university pain specialist were compared with patients who were not on metformin. We compared the pain outcomes in 46 patients on metformin and 94 patients not taking metformin therapy. The major finding was that metformin use was associated with a decrease in the mean of "pain now," by -1.85 (confidence interval: -3.6 to -0.08) on a 0-10 visual analog scale, using a matched propensity scoring analysis and confirmed using a Bayesian analysis, with a significant mean decrease of -1.36 (credible interval: -2.6 to -0.03). Additionally, patients on metformin showed a non-statistically significant trend toward decreased pain on a variety of other pain descriptors. Our proof-of-concept findings suggest that metformin use is associated with a decrease in lumbar radiculopathy pain, providing a rational for larger retrospective trials in different pain populations and for prospective trials, to test the effectiveness of metformin in reducing neuropathic pain.

KW - Adenosine monophosphate activated kinase

KW - Diabetes

KW - mTOR

KW - Neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84889781116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889781116&partnerID=8YFLogxK

U2 - 10.2147/JPR.S52205

DO - 10.2147/JPR.S52205

M3 - Article

AN - SCOPUS:84889781116

VL - 6

SP - 755

EP - 763

JO - Journal of Pain Research

JF - Journal of Pain Research

SN - 1178-7090

ER -